Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
Trastuzumab resistance, which is a common therapeutic challenge in HER2 positive metastatic
breast cancer, is not fully understood. Pyrotinib is an oral tyrosine kinase inhibitor
targeting EGFR, HER-2 and HER-4 receptors. More general inhibition of ErbB family with
pyrotinib could provide additional benefit. This study is designed to evaluate the efficacy
and safety of pyrotinib in combination with capecitabine in patients with HER2 positive
locally advanced or metastatic breast cancer who had early failure on or after trastuzumab
treatment.